Synnovation is committed to developing breakthrough precision medicines addressing significant unmet medical needs. Our pipeline is built around highly validated precision oncologic targets where greater potency and selectivity and optimized pharmaceutical and drug-like properties have the potential to address liabilities in existing standards of care, and meaningfully improve patient outcomes.